Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C : A Meta-Analysis of Randomized Controlled Trials
Joint Authors
Yang, Zongguo
Chen, Xiaorong
Yang, Lei
Zhuang, Liping
Source
Gastroenterology Research and Practice
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-04-11
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Background.
The efficacy and tolerability of peginterferon α-2a and peginterferon α-2b in chronic hepatitis C (CHC) patients remain controversial.
Methods.
PubMed, Ovid, and Cochrane libraries were electronically searched until August 30, 2012.
Studies that met the inclusion criteria were systematically evaluated by two reviewers independently.
Results.
The overall sustained virologic response (SVR) rate of the peginterferon α-2a group was significantly higher than that of the peginterferon α-2b group (46.7% versus 42.4%, P value = 0.01).
The same tendency was observed for naïve, genotype 1/4, and genotype 2/3 patients.
The early virologic response (EVR) and end-of-treatment response (ETR) rates were significantly higher in the peginterferon α-2a group than in the peginterferon α-2b group (56.1% versus 49.8%, P<0.0001; 67.9% versus 56.6%, P<0.00001, resp.).
Peginterferon α-2a had a significantly lower discontinuation rate than peginterferon α-2b (27.9% versus 33.9%, P<0.0001) in naïve patients.
In both naïve CHC and hepatitis C virus genotype 1 patients, peginterferon α-2a had a higher relapse rate than peginterferon α-2b.
Conclusions.
Peginterferon α-2a has superior efficacy with higher EVR, ETR, and SVR than peginterferon α-2b for CHC patients, both plus ribavirin.
Peginterferon α-2a might obtain a similar or even lower discontinuation rate than peginterferon α-2b.
However, peginterferon α-2a had a higher relapse rate than peginterferon α-2b.
American Psychological Association (APA)
Yang, Zongguo& Zhuang, Liping& Yang, Lei& Chen, Xiaorong. 2013. Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C : A Meta-Analysis of Randomized Controlled Trials. Gastroenterology Research and Practice،Vol. 2013, no. 2013, pp.1-11.
https://search.emarefa.net/detail/BIM-494816
Modern Language Association (MLA)
Yang, Zongguo…[et al.]. Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C : A Meta-Analysis of Randomized Controlled Trials. Gastroenterology Research and Practice No. 2013 (2013), pp.1-11.
https://search.emarefa.net/detail/BIM-494816
American Medical Association (AMA)
Yang, Zongguo& Zhuang, Liping& Yang, Lei& Chen, Xiaorong. Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C : A Meta-Analysis of Randomized Controlled Trials. Gastroenterology Research and Practice. 2013. Vol. 2013, no. 2013, pp.1-11.
https://search.emarefa.net/detail/BIM-494816
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-494816